SMAD2 mRNA levels were significantly downregulated in prostate carcinomas compared to normal prostate tissue, and even more so at metastatic compared to primary tumor sites (Fig. 7a,b and Supplementary Fig. S7). Here, SMAD2 is linked to prostate carcinoma.